phamous
pharmacotherapy monitoring and outcome survey

PHArmacotherapy Monitoring and OUtcome Survey

Jaarlijkse evaluatie van de mentale en lichamelijke gezondheid van antipsychotica gebruikers

Shiral Gangadin, coördinator PHAMOUS, RGOc, UMCG
Geen (potentiële) belangenverstrengeling
s.s.gangadin@umcg.nl

RGOc
ggz Drenthe geestelijke gezondheidszorg
umcg
GGZ Friesland
Lentis

21 maart 2025

PHAMOUS-onderzoekers

Wim Veling

Sander de Vos

Edith Liemburg

Marieke Pijnenborg

Johan Arends

Lisette van der Meer

Stynke Castelein

Lokale PHAMOUS-coördinatoren

UCP:

Marjolein Haak

Marrit Rozestraten

Lentis:

Bart Hokke

Margreet Mulder, Lianne Sanders

GGZ Drenthe:

Assen: Yolanda Zantige

Emmen: Jeanette Smit

Hoogeveen: Piet Groenia, Bea Wolbink

Meppel: Theo de Jonge, Jeltje Lunenborg

GGZ Friesland:

Magda Hendriks

GGNet:

Wanda Pol

Aanleiding PHAMOUS



Snyder & Murphy, *Nat Rev Drug Disc*, 2008

Metingen

Domein	Naam	MOPHAR	PHAMOUS
Lichamelijke gezondheid	*Lichamelijk onderzoek*	✓	✓
	Somatische anamnese	✓	✓
	Lab-bepalingen	✓	✓
Medicatie	*Medicatiegebruik*	✓	✓
	Bijwerkingen (SMS)	✓	✓
	Medicatietrouw (MARS-6)	✓	✓
Leefstijl	*Leefstijlvragenlijst*	✓	✓
	Middelengebruik	✓	✓
Herstel	*I-ROC*	✓	✓
Symptomen	*OQ-45*	✓	✗
	PANSS	✗	✓
Functioneren	*WHODAS 2.0*	✓	✓
	Happiness Index	✓	✓
Bewegingsstoornissen	*St. Hans Rating Scale*	✗	✓
Aanvullende screening	*ISI*	✓	✗
	PCL-5, JTV (intake)	✓	✗
Overig	*Zorggebruik*	✗	✓
	Tevredenheid zorg	✗	✓

Rapportage

Metingen



Updaten behandelplan
Shared Decision Making

Rapport

Behandelaar

Cliënt

Rapport huisarts

Knelpunten

Metingen



Updaten behandelplan
Shared Decision Making

Rapport

Behandelaar

Cliënt

Rapport huisarts

Aantal metingen



→ Dus: “Geen zorgafstemmingsgesprek zonder PHAMOUS”

Terugkoppeling/implementatie

Table 3. Prevalence of Treatment Recommendation and Treatment Prescriptions[a]

Disposition of Treatment	Assessment 1	Assessment 2	Assessment 3	Wald χ^2	*P*
Treatment was recommended					
Overall	51.9 (654)	55.8 (703)	59.3 (746)	25.15	<.001**
Antihypertensive drugs	42.0 (529)	43.9 (553)	45.8 (576)	6.29	.043*
Lipid-lowering drugs	21.0 (264)	27.6 (347)	31.5 (397)	72.3	<.001**
Antihyperglycemic drugs (fasting glucose)	8.0 (70)	8.7 (87)	10.2 (102)	1.53	.464
Antihyperglycemic drugs (total glucose)	7.1 (90)	8.3 (104)	9.2 (116)	10.67	.005**
Patients receiving the recommended treatment					
Overall	43.0 (281)	48.2 (339)	50.4 (376)	41.74	<.001**
Antihypertensive drugs	31.0 (164)	35.3 (195)	37.8 (218)	18.83	<.001**
Lipid-lowering drugs	56.1 (148)	55.0 (191)	55.7 (221)	11.99	.002**
Antihyperglycemic drugs (fasting glucose)	74.3 (52)	77.0 (67)	72.5 (74)	0.49	.784
Antihyperglycemic drugs (total glucose)	76.7 (69)	77.9 (81)	74.1 (86)	0.83	.661
Patients not receiving the recommended treatment					
SBP ≥ 155 mm Hg	14.8 (54)	16.5 (59)	18.7 (67)	…	…
Serum LDL cholesterol level ≥ 4.0 mmol/L	35.3 (41)	32.7 (51)	25.6 (45)	…	…
Fasting serum glucose level ≥ 8.5 mmol/L	16.7 (3)	15.0 (3)	25.0 (7)	…	…
Total serum glucose level ≥ 8.5 mmol/L	23.8 (5)	17.4 (4)	23.3 (7)	…	…

[a]Values at each assessment shown as % (n). N = 1,259 at all 3 assessments.
*Significant at α < .05. **Significant at α < .01.
Abbreviations: LDL = low-density lipoprotein, SBP = systolic blood pressure.
Symbol: … = not applicable.

Bruins et al., *2017, the J of Clin Psych.*

Knelpunten

Metingen



Updaten behandelplan
Shared Decision Making

Rapport

Behandelaar

Cliënt

Rapport huisarts

Meten is weten(schap)!

Totaal 30 wetenschappelijke publicaties sinds 2008

ELSEVIER

Contents lists available at ScienceDirect

Journal of Psychiatric Research

journal homepage: www.elsevier.com/locate/jpsychires

Financial dissatisfaction in people with psychotic disorders - A short report on its prevalence and correlates in a large naturalistic psychosis cohort

J.L. Jansen [a,*], R. Bruggeman [a,b], H.A.L. Kiers [c], PHAMOUS-investigators, G.H.M. Pijnenborg [a,d], S. Castelein [a,b,e], W. Veling [f], E. Visser [b], L. Krabbendam [g], J. Koerts [a]

phamous

pharmacotherapy monitoring and outcome survey

Shiral Gangadin, coördinator PHAMOUS
s.s.gangadin@umcg.nl

RGOc

21 maart 2024

Extra slides

Doeleinden ROM-PHAMOUS

- **Cliënt:**
  - Sinds 2006 jaarlijkse screening om effecten langdurig antipsychotica-gebruik te monitoren
  - In kaart brengen van mentale, fysieke en sociale gesteldheid
  - Cliënttevredenheid en herstel
- **Behandelaar:**
  - Update voor behandelplan
- **Optimaliseren zorgverlening**
  - verplichting t.o.v. zorgverzekeraar
- **<u>Wetenschappelijk onderzoek</u>**

** ROM: Routine Outcome Monitoring*

Metabool risico antipsychotica

Table 1. Relative Effect of SGAs on Metabolic Disturbances

Generic (Trade Name)	Weight Gain	Dyslipidemia	T2DM
Olanzapine (Zyprexa)	High	High	High
Clozapine (Clozaril)	High	High	High
Risperidone (Risperdal)	Moderate	Low to moderate	Low
Ziprasidone (Geodon)	Low	Low	Low
Quetiapine (Seroquel)	Moderate	Moderate	Low to moderate
Aripiprazole (Abilify)	Low	Low	Low
Paliperidone (Invega)[a]	Low	Low	Low
Asenapine (Saphris)[a]	Low to moderate	Low	Unknown
Iloperidone (Fanapt)[a]	Low to moderate	Low	Unknown

[a] Due to the limited trial data for these agents, their metabolic-effect profiles are based on the package insert.
SGA: second-generation antipsychotic; T2DM: type 2 diabetes mellitus.
Source: References 1, 6.

Church, Hamer & Ulbrich, *US* Pharm, 2010

Training en Bijscholing

- **PHAMOUS basistraining**
- **PANSS training**
- **St Hans Rating Scale (SHRS) / EPS training**

Zie: https://www.rgoc.nl/trainingen/